Can Intuition Drive Drug Discovery? - Brian Arey part 2

Brian Arey's most important discoveries started with intuition. Not a literature review. Not a grant proposal. A gut feeling - and then years of turning it into data nobody outside his company would ever see. This is what early drug discovery looks like from the inside, in an industry where being right is not the same as being recognized. About Brian Arey Arey is a pharmacologist and physiologist with over 25 years in pharmaceutical research at Bristol-Myers Squibb. He has worked across neuroscience, reproductive endocrinology, bone biology, thrombosis, and cardiovascular mechanotransduction - never by plan, always by need. He has led mechanistic pharmacology teams and served as interim head of a 70-person cross-functional research organization. He is the kind of scientist who generates the foundational data that makes drugs possible, and rarely gets the credit that follows. What You'll Learn Why drug discovery intuition is not guesswork - and what separates a productive gut feeling from wishful thinking when no data yet exists How leading a 70-person research organization without micromanaging actually works - and why the people at the bench usually know more than the person running the meeting What the "killer experiment" concept taught Arey about knowing when to stop investing in a hypothesis before it costs the team everything Why working across six therapeutic areas in one career is both a scientific advantage and a professional liability that most scientists are not warned about How negative data functions in early drug discovery - and why the science that never gets published is often the science that matters most What it means to build a career in industry anonymity and still find the work worth doing Episode Timeline 00:00 Introduction and ecosystem updates 01:30 Recap from Part 1 and leading 70 people on an interim basis 03:10 Leadership style: trust, communication, and why fun is not optional 08:58 Drug discovery from first principles: from pathophysiology to target selection 16:49 Organizational patience and the go/no-go decision in early discovery 23:09 GPR56 as a GPCR mechanosensor - knowing the answer a decade early 27:35 Intellectual humility and drug discovery as a team sport 37:10 The KLF2 pathway and GPCRs in atherosclerosis: an unfinished story 42:39 Jack of all trades: how career breadth shapes drug discovery thinking 49:18 When programs get cancelled: the emotional reality and what comes next 57:50 Introverts, scientific identity, and putting yourself out there 01:05:19 Intuition vs. data: how hypotheses are actually born Build the skills your GPCR research demands. The GPCR University is where working scientists go to go deeper - structured learning, a serious community, and resources you will not find anywhere else. Access it here: https://www.ecosystem.drgpcr.com/gpcr... Get to know our Partners. Eurofins DiscoverX provides the assay platforms that bring GPCR pharmacology into sharper focus - from functional selectivity to receptor trafficking. Learn what they offer: https://www.ecosystem.drgpcr.com/euro.... GeneTex supplies the antibody-grade specificity that rigorous GPCR research requires. See their validated reagents: https://www.ecosystem.drgpcr.com/genetex Tags GPCR, drug discovery, GPCR pharmacology, pharmacology, mechanotransduction, GPR56, KLF2, atherosclerosis, endothelial cells, apixaban, Eliquis, pharmaceutical research, industry pharmacology, receptor signaling, GPCR drug discovery, Dr GPCR, GPCR podcast, target validation, drug discovery process, early discovery, Bristol Myers Squibb Hashtags #DrGPCR #GPCR #DrugDiscovery #Pharmacology #GPCRResearch #Mechanotransduction #IndustryScience